Andrei Alexandrov, MD
Neurology · Memphis, TNNPI 1861526915
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,345 of the $224,677 with a category attached, or 70.5%. AstraZeneca accounts for 60.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $81,952 and has fallen 97.1% since, to $2,378 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $936.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$135K
- Genentech USA, Inc.$75K
- Novo Nordisk$9K
- Medtronic$1K
- Imperative Care, Inc$1K
- Longeviti Neuro Solutions Inc$875
- plus $3K from 14 others
Across 2 payments — averaging $6188.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$8K
- Boehringer Ingelheim$5K
What the payments were for
- Consulting fees$19,4149%
- Speaking & faculty fees$158,34570%
- Travel & lodging$35,85616%
- Food & beverage$11,0255%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 120 | $135,209 |
| Genentech USA, Inc. | 47 | $74,540 |
| Novo Nordisk | 8 | $8,905 |
| Medtronic(3 entities) | 22 | $1,246 |
| Imperative Care, Inc | 3 | $1,147 |
| Longeviti Neuro Solutions Inc | 6 | $875 |
| Viz.ai, Inc. | 8 | $622 |
| Ceribell, Inc. | 4 | $344 |
| BTG International Inc. | 3 | $315 |
| Microvention, Inc. | 2 | $266 |
| Chiesi USA, Inc. | 6 | $251 |
| Genentech, Inc. | 3 | $234 |
| Tonix Medicines, Inc. | 1 | $198 |
| Penumbra, Inc. | 1 | $150 |
| Hyperfine Operations, Inc. | 1 | $123 |
| Boston Scientific | 1 | $108 |
| Abbott | 1 | $56 |
| Bayer | 1 | $33 |
| Stryker | 1 | $28 |
| Portola Pharmaceuticals, LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRILINTA$123,535
- Activase$47,979
- ANDEXXA$7,654
- ZOOM 88-T LARGE DISTAL PLATFORM$1,035
- CLEARFIT$534
- Viz.AI LVO$429
- SOLITAIRE X$305
- POCKET EEG DEVICE$283
- LINQ II$228
- Solitaire$203
- ZEMBRACE SYMTOUCH$198
- TOSYMRA$198
- InvisiShunt Implant Kit$173
- RED 72$150
- Swoop$123
- CARDENE$113
- CLEVIPREX$113
- Watchman$108
- TNKase$106
How this compares
$224,677 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Memphis
- Lucas ElijovichMemphis$415K
- Mark LedouxMemphis$352K
- Khalid AlsherbiniMemphis$249K
- Tulio BertoriniMemphis$160K
- Rozita KhaliliMemphis$91K
- Michael LevinMemphis$47K
- Michael JacewiczMemphis$33K
- James WangMemphis$27K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.